Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 12:13 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 2,795 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Combination Group Clear all

Conditions: Asthma
Interventions: Dupilumab, Placebo, Inhaled corticosteroid (ICS) therapy, Albuterol/Salbutamol, Levalbuterol/Levosalbutamol; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 12 Years and older
Enrollment: 1,902 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 116
States / cities: Birmingham, Alabama • Flagstaff, Arizona • Gilbert, Arizona + 100 more

Conditions: HIV
Interventions: DV700P-RNA 100 mcg, DV701B1.1-RNA 100 mcg; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 9
States / cities: Birmingham, Alabama • Atlanta, Georgia • Decatur, Georgia + 6 more

Conditions: Type 2 Diabetes Mellitus
Interventions: Insulin glargine /lixisenatide Fixed Ratio Combination, Insulin glargine, Metformin (Background drug); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 323 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 14
States / cities: Little Rock, Arkansas • Paramount, California • Larenceville, Georgia + 11 more

Conditions: T Acute Lymphoblastic Leukemia, T Lymphoblastic Lymphoma
Interventions: Asparaginase, Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Leucovorin Calcium, Mercaptopurine, Methotrexate, Nelarabine, Pegaspargase, Prednisone, Radiation Therapy, Thioguanine, Vincristine Sulfate; Drug · Other · Radiation
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 1 Year to 30 Years
Enrollment: 1,895 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2025
U.S. locations: 191
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 143 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Ensifentrine 3 mg, Glycopyrrolate 21.25 mcg, Glycopyrrolate 42.5 mcg, Placebo; Drug
Lead sponsor: Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 497 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 57
States / cities: Dothan, Alabama • Phoenix, Arizona • Tucson, Arizona + 49 more

Conditions: Measles-Mumps-Rubella
Interventions: Priorix, M-M-R II, Kinrix, ProQuad; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 4 Years to 6 Years
Enrollment: 4,011 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2015
U.S. locations: 50
States / cities: Birmingham, Alabama • Tucson, Arizona • Benton, Arkansas + 44 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: ADVAIR DISKUS™ 250/50mcg, Placebo; Drug · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 50 Years and older
Enrollment: 249 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 24
States / cities: Birmingham, Alabama • Jasper, Alabama • Mobile, Alabama + 21 more

Conditions: Spine Surgery, Back Pain
Interventions: High Dose Tranexamic acid, Low Dose Tranexamic acid, Tranexamic acid Topical, Normal saline; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years to 80 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Occupational Stress
Interventions: Mindfulness Based Stress Reduction, Daily Examen spiritual practice, Stress inoculation combination; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 390 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Acute Myeloid Leukemia, Acute Myeloid Leukemia With Multilineage Dysplasia Following, Myelodysplastic Syndrome, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Recurrent Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia
Interventions: midostaurin, Bortezomib, mitoxantrone hydrochloride, etoposide, cytarabine; Drug
Lead sponsor: Alison Walker; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Drug Abuse
Interventions: STAGE-12, Treatment as Usual; Behavioral
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 471 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 10
States / cities: Jacksonville, Florida • Kaneohe, Hawaii • Columbus, Ohio + 7 more

Conditions: Chronic Pain
Interventions: Hydrocodone; Drug
Lead sponsor: NEMA Research, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 2
States / cities: Naples, Florida • Leawood, Kansas

Conditions: Type 2 Diabetes Mellitus
Interventions: Lantus (Insulin glargine), HOE901-U300 (new formulation of insulin glargine); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 811 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 110
States / cities: Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 90 more

Conditions: Difficult Endotracheal Intubation
Interventions: aScope (Ambu Inc. 6740 Baymeadow Drive Glen Burnie, MD), Control; Device
Lead sponsor: University of Louisville; Other
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Burnout, Professional, Emotional Intelligence, Peer Influence
Interventions: READ-SG Sessions; Behavioral
Lead sponsor: Columbia University; Other
Eligibility: 21 Years and older
Enrollment: 137 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: New York, New York

Conditions: Hepatitis C, Chronic
Interventions: BI 207127-placebo: 8-week treatment, Ribavirin: 24-week treatment, BI 207127: 24-week treatment, Faldaprevir: 24-week treatment, Ribavirin-placebo: 8-week treatment, Faldaprevir-placebo: 8-week treatment, Faldaprevir: 16-week treatment, Ribavirin: 16-week treatment, RBV: 24-week treatment, BI 207127: 16-week treatment; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 496 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 31
States / cities: North Little Rock, Arkansas • Anaheim, California • Bakersfield, California + 28 more

Conditions: CoronaVirus Disease-2019 (COVID-19)
Interventions: ABBV-47D11, Placebo for ABBV-47D11, ABBV-2B04, Placebo for ABBV-2B04; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 11
States / cities: Glendale, California • Cutler Bay, Florida • Miami, Florida + 8 more

Conditions: HIV Infections
Interventions: rgp120/HIV-1 SF-2, Env 2-3, HIVAC-1e, gp160 Vaccine (MicroGeneSys); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 1994
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Hypertension
Interventions: Darusentan, Darusentan Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 35 Years to 80 Years
Enrollment: 352 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 67
States / cities: Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 62 more

Conditions: Menopause
Interventions: Estradiol , estriol , progesterone, estradiol, progesterone, estriol, progesterone, equine estrogens m-progesteroneacetate; Drug
Lead sponsor: Jeanne Drisko, MD, CNS, FACN; Other
Eligibility: 40 Years to 65 Years · Female only
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2014
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Healthy Adult
Interventions: Traditional Hangboard Protocol, Extensor Tendon Isometric Training; Other
Lead sponsor: April Henderson; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: HIV Infections
Interventions: TRUVADA + Raltegravir; Drug
Lead sponsor: Fenway Community Health; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Other Cancer
Interventions: Complement Theory's Live CoActive Exercise Coaching and Personalized Digital Application, Digital application with expert guidelines on lifestyle modification; Behavioral
Lead sponsor: Complement Theory Inc.; Industry
Eligibility: 21 Years and older
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Dover, Delaware

Conditions: Lymphoma, Non-Hodgkin, HIV Infections
Interventions: Bleomycin sulfate, Vincristine sulfate, Doxorubicin hydrochloride, Cyclophosphamide, Allopurinol, Methotrexate, Cytarabine, Leucovorin calcium, Zidovudine, Dexamethasone; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 19 Years to 69 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1990
U.S. locations: 14
States / cities: Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 6 more

Search by objective public record fields.

Evaluation of Dupilumab in Patients With Persistent Asthma (Liberty Asthma Quest)

A Trial to Evaluate the Safety and Tolerability of DV700P-RNA and DV701B1.1-RNA Immunization in Combination With Antiretroviral Analytical Treatment Interruption (ATI) in People Living With HIV for Elicitation of V3-glycan Antibodies

Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Combination Versus Insulin Glargine Alone on Top of Metformin in Type 2 Diabetic Patients

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma

Clinical Study of Ensifentrine-Glycopyrrolate (MK-5884A/RPL554) Fixed-dose Combination Dose Ranging in Participants With COPD (MK-5884A-029/RPL554-CO-212)

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Subjects Four to Six Years of Age

A 16-Week Study to Evaluate the Effect of Advair DISKUS™ 250/50mcg on Arterial Stiffness in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Combined IV and Topical TXA in Major Spine Surgery

Selah Trial of Stress Interventions for Clergy: Mindfulness Based Stress Reduction, Daily Examen, and Stress Inoculation

Phase I Combination of Midostaurin, Bortezomib, and Chemo in Relapsed/Refractory Acute Myeloid Leukemia

Stimulant Abuser Groups to Engage in 12-Step

Pharmacokinetic Study of Hydrocodone/APAP in Chronic Pain Patients

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy

Video-laryngoscope With a Novel Video-stylet for Difficult Intubation

The READ-SG Study: Effect of Peer-Facilitated Small Group Discussions

Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2

Study to Assess Adverse Events and How Intravenous (IV) ABBV-47D11 and IV ABBV-2B04 Given Alone and in Combination Moves Through the Body of Adult Participants With Coronavirus Disease 2019 (COVID-19)

A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of a Recombinant Vaccinia-HIV Envelope Vaccine (HIVAC-1e) in Combination With a Panel of Subunit Recombinant HIV Envelope Vaccines

DORADO - Fixed Doses of Darusentan as Compared to Placebo in Resistant Hypertension

Bioidentical 'Natural' Hormone Evaluation in Early Menopause

The Effects of Finger Extensor Training on Climbing Performance Compared With Traditional Flexor Training

HIV Non Occupational Post-Exposure Prophylaxis (PEP)

A Randomised Controlled Trial to Evaluate the Impact of Complement Theory's Live CoActive Exercise Coaching and Personalized Digital Application on Cancer Survivors' Quality of Life

Chemotherapy and Azidothymidine, With or Without Radiotherapy, for High Grade Lymphoma in AIDS-Risk Group Members